Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis

Revusiran is a 1st-generation short interfering RNA targeting transthyretin conjugated to an N-acetylgalactosamine ligand to facilitate delivery to hepatocytes via uptake by the asialoglycoprotein receptors. Revusiran, in development for the treatment of hereditary transthyretin-mediated amyloidosis...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nucleic Acid Ther
Autors principals: Sutherland, Jessica E., Hettinger, Julia L., Chan, Amy, Gilbert, Jason, Warner, Garvin L., Davis, Wendell P.
Format: Artigo
Idioma:Inglês
Publicat: Mary Ann Liebert, Inc., publishers 2020
Matèries:
Original Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6987735/
https://ncbi.nlm.nih.gov/pubmed/31821125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/nat.2019.0796
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars